Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CASR | P41180 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | TTR | P02766 | 1/20 | 0.38 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.38 |
| ▸ | NT5E | P21589 | 1/20 | 0.37 |
| ▸ | XIAP | P98170 | 1/20 | 0.36 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.36 |
| ▸ | PLAU | P00749 | 1/20 | 0.35 |
| ▸ | NCF1 | P14598 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31544789 | 1.00 | NOS3 (0.41) | NOS3NOS2TSHRALDH1A1HSD17B10 | |
| SCHEMBL8847325 | 0.84 | TSHR (0.42) | TSHRALDH1A1HSD17B10TDP1CASR | |
| Sulfuric Acid SCHEMBL2243571 | 0.81 | NOS2 (0.48) | NOS3NOS2TSHRALDH1A1HSD17B10 | |
| SCHEMBL17647899 | 0.80 | NOS3 (0.43) | NOS3NOS2TSHRTDP1ASIC3 | |
| SCHEMBL30253319 | 0.78 | NOS3 (0.46) | NOS3NOS2ALDH1A1KDM4EASIC3 | |
| Ammonia Solution, Strong SCHEMBL28206444 | 0.78 | NOS3 (0.41) | NOS3NOS2TSHRTDP1ASIC3 | |
| SCHEMBL9179403 | 0.78 | TSHR (0.43) | TSHRALDH1A1CASRSMN1; SMN2 | |
| SCHEMBL9176772 | 0.77 | TSHR (0.42) | TSHRALDH1A1CASRSMN1; SMN2 | |
| SCHEMBL9174597 | 0.77 | TSHR (0.42) | TSHRALDH1A1CASRSMN1; SMN2 | |
| SCHEMBL9176169 | 0.77 | TSHR (0.42) | TSHRALDH1A1CASRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036208-B2 | Methods for treating neurodegenerative disorders | ALZHEON, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12036208-B2 | Methods for treating neurodegenerative disorders | ALZHEON, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-RE49569-E1 | Alkylamine derivative | EA PHARMA CO., LTD. (JP) | 2023-07-04 | — | — | US | disclosed |
| US-11077095-B2 | Methods for treating neurodegenerative disorders | ALZHEON, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| CN-108950645-B | Aluminum and aluminum alloy anodic oxidation nickel-free sealing agent | 上海铝通化学科技有限公司 | 2020-10-23 | — | — | CN | disclosed |
| CN-108950645-A | A kind of aluminium and aluminium alloy anode oxide are without nickel sealer | 上海铝通化学科技有限公司 | 2018-12-07 | — | — | CN | disclosed |
| EP-2546231-B1 | ALKYLAMINE DERIVATIVE | EA PHARMA CO LTD (JP) | 2018-11-07 | — | — | EP | disclosed |
| US-9561216-B2 | Alkylamine derivative | EA PHARMA CO., LTD. (JP) | 2017-02-07 | — | — | US | disclosed |
| US-20160101091-A1 | ALKYLAMINE DERIVATIVE | AJINOMOTO CO., INC. (JP) | 2016-04-14 | — | — | US | disclosed |
| US-9253997-B2 | Alkylamine derivative | AJINOMOTO CO., INC. (JP) | 2016-02-09 | — | — | US | disclosed |
| CN-1802610-A | Polyhydroxyalkanoate containing amide group, sulfonic acid group and sulfonate group, method for producing the same, and charge control agent, toner, image forming method and image forming apparatus | CANON KK (JP) | 2006-07-12 | — | — | CN | disclosed |
| US-20060014921-A1 | Polyhydroxyalkanoate containing amide group, sulfonic group, and sulfonate ester group, method for producing the same, and charge control agent, toner, image forming method, and image forming apparatus | CANON KABUSHIKI KAISHA (JP) | 2006-01-19 | — | — | US | disclosed |
| US-20050287484-A1 | Resin-coated carrier for electrophotographic developer | CANON KABUSHIKI KAISHA (JP) | 2005-12-29 | — | — | US | disclosed |
| WO-2005121904-A1 | CHARGE CONTROL AGENT, TONER, IMAGE FORMING METHOD, AND IMAGE FORMING APPARATUS | CANON KABUSHIKI KAISHA (JP) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005121207-A2 | POLYHYDROXYALKANOATE HAVING VINYL GROUP, ESTER GROUP, CARBOXYL GROUP, AND SULFONIC GROUP, AND METHOD OF PRODUCING THE SAME | CANON KABUSHIKI KAISHA (JP) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005121204-A2 | POLYHYDROXYALKANOIC ACID HAVING VINYL, ESTER, CARBOXYL OR SULFONIC ACID GROUP AND PRODUCING METHOD THEREFOR | CANON KABUSHIKI KAISHA (JP) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005121205-A2 | POLYHYDROXYALKANOATE HAVING ESTER GROUP, CABOXYL GROUP, AND SULFONIC GROUP, AND METHOD OF PRODUCING THE SAME | CANON KABUSHIKI KAISHA (JP) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005121206-A2 | POLYHYDROXYALKANOATE HAVING VINYL GROUP, ESTER GROUP, CARBOXYL GROUP AND SULFONIC ACID GROUP, AND PRODUCTION METHOD THEREOF | CANON KABUSHIKI KAISHA (JP) | 2005-12-22 | — | — | WO | disclosed |
| EP-1579277-A1 | POLYHYDROXYALKANOATE CONTAINING AMIDE GROUP, SULFONIC GROUP, AND SULFONATE ESTER GROUP, METHOD FOR PRODUCING THE SAME, AND CHARGE CONTROL AGENT, TONER, IMAGE FORMING METHOD, AND IMAGE FORMING APPARATUS | Canon Kabushiki Kaisha (JP) | 2005-09-28 | — | — | EP | disclosed |
| WO-2004061530-A1 | POLYHYDROXYALKANOATE CONTAINING AMIDE GROUP, SULFONIC GROUP, AND SULFONATE ESTER GROUP, METHOD FOR PRODUCING THE SAME, AND CHARGE CONTROL AGENT, TONER, IMAGE FORMING METHOD, AND IMAGE FORMING APPARATUS | CANON KABUSHIKI KAISHA (JP) | 2004-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11077095-B2 | Methods for treating neurodegenerative disorders | NLN, CLN6, SNCA | NOS3 2091/4885NOS2 2550/4885TSHR 4525/4885 |
| US-12036208-B2 | Methods for treating neurodegenerative disorders | NLN, CLN6, SNCA | NOS3 2091/4885NOS2 2550/4885TSHR 4525/4885 |
| US-20160101091-A1 | ALKYLAMINE DERIVATIVE | CASR, TAAR5, TAAR1 | NOS3 1972/4885NOS2 1694/4885TSHR 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.